FindTrial
Sign In

Frequency of occurrence by risk-based response to infusion reaction upon rituximab administration in patients with B-cell non-Hodgkin's lymphoma

Frequency of occurrence by risk-based response to infusion reaction upon rituximab administration in patients with B-cell non-Hodgkin's lymphoma - Frequency of occurrence by risk-based response to infusion reaction upon rituximab administration in patients with B-cell non-Hodgkin's lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000032309
Enrollment
70
Registered
2018-04-19
Start date
2018-04-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

B-cell non-Hodgkin&#39

Interventions

Patients with low-grade lymphoma (-), bulky mass (&gt
10 cm) (-) are administered rituximab at normal rates. Patients with low-grade lymphoma (+), bulky mass (tumor size&gt
10 cm) (-) or low-grade lymphoma (-), bulky mass (tumor diameter&gt
10 cm) (+), prophylactic administration of corticosteroids Rituximab is administered at normal rate. Patients with low-grade lymphoma (+), bulky mass (&gt
10 cm) (+) are administered prophylactic corticosteroids, and rituximab is administered at the maximum administration rate.

Sponsors

Nihon University Itabashi Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: B cell non-Hodgkin lymphoma patients

Exclusion criteria

Exclusion criteria: Patients who have been treated with rituximab in the past

Design outcomes

Primary

MeasureTime frame
Incidence rate of infusion reaction in each risk group at the time of initial administration of rituximab—

Countries

Japan

Contacts

Public ContactKatsuhiro Miura

Nihon University School of Medicine Department of Hematology and Rheumatology

miura.katsuhiro@nihon-u.ac.jp03-3972-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026